Clinical study on mpMRI/TRUS software fusion-guided transperineal prostate biopsy

Background: To enhance prostate cancer diagnosis, multiparametric Magnetic Resonance Imaging (mpMRI) combined with Transrectal Ultrasound (TRUS) fusionguided biopsy has emerged as a promising technique. This study aimed to evaluate its clinical benefits over traditional TRUS-guided biopsy. Methods: A retrospective analysis was performed on 83 patients diagnosed between January 2022 and April 2024. Patients were divided into two groups: 41 underwent mpMRI/TRUS fusion-guided biopsy, while 42 had traditional TRUS-guided biopsy. The baseline characteristics of both groups were similar, facilitating a direct comparison of diagnostic efficacy and complication rates. Results: The fusion-guided group showed a significantly higher detection rate of clinically significant prostate cancer (21/41 vs. 12/42, p = 0.035). It also detected more clinically significant cases (20/41 vs. 11/42, p = 0.033). Notably, the fusion group experienced fewer complications, including no instances of hematochezia (p = 0.003) or infections (p = 0.012), and reported lower postoperative pain levels (Visual Analog Scale score 1.8 +/- 0.78 vs. 2.33 +/- 1.07, p = 0.012). Conclusions: The integration of mpMRI with TRUS in fusion-guided biopsy enhances the accuracy of detecting clinically significant prostate cancer, reduces procedural complications, and minimizes patient discomfort. This approach represents a significant advancement in prostate cancer management, improving both diagnostic outcomes and patient safety.